insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

Collaboration applies insitro’s Virtual Human causal AI discovery platform to two diseases defined by patient heterogeneity and high unmet medical need insitro to receive $40 million upfront and up to… The post insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies appeared first on insitro .